U. Restelli, A. Alberti, A. Lazzarin, M. Bonfanti, C. Nappi, and D. Croce, “Budget impact analysis of the use of daclatasvir in Italy for the treatment of Hepatitis C Virus (HCV) genotype 3 patients”, FE, vol. 17, no. 1, pp. 7–12, Mar. 2016.